切换至 "中华医学电子期刊资源库"

中华肝脏外科手术学电子杂志 ›› 2017, Vol. 06 ›› Issue (04) : 320 -323. doi: 10.3877/cma.j.issn.2095-3232.2017.04.019

所属专题: 文献

临床研究

熊去氧胆酸治疗原发性胆汁性肝硬化临床疗效的Meta分析
顾静娴1, 曲凯1, 刘昌1,()   
  1. 1. 710061 西安交通大学医学院第一附属医院肝胆外科
  • 收稿日期:2017-04-30 出版日期:2017-08-10
  • 通信作者: 刘昌
  • 基金资助:
    国家自然科学基金(81472247); 西安交通大学第一附属医院临床研究重点项目(XJTU1AF-CRF-2015-003)

Clinical efficacy of ursodesoxycholic acid for the treatment of primary biliary cirrhosis: a Meta-analysis

Jingxian Gu1, Kai Qu1, Chang Liu1,()   

  1. 1. Department of Hepatobiliary Surgery, the First Affiliated Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an 710061, China
  • Received:2017-04-30 Published:2017-08-10
  • Corresponding author: Chang Liu
  • About author:
    Corresponding author:Liu Chang, Email:
引用本文:

顾静娴, 曲凯, 刘昌. 熊去氧胆酸治疗原发性胆汁性肝硬化临床疗效的Meta分析[J]. 中华肝脏外科手术学电子杂志, 2017, 06(04): 320-323.

Jingxian Gu, Kai Qu, Chang Liu. Clinical efficacy of ursodesoxycholic acid for the treatment of primary biliary cirrhosis: a Meta-analysis[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2017, 06(04): 320-323.

目的

探讨熊去氧胆酸(UCDA)治疗原发性胆汁性肝硬化(PBC)的临床疗效及安全性。

方法

计算机检索2016年10月之前PubMed、万方学术期刊全文数据库、中国知网(CNKI)收录的关于UDCA治疗PBC的随机对照试验文献。英文检索词:ursodeoxycholic acid、ursodiol、primary biliary cirrhosis、random clinical trials。中文检索词:熊去氧胆酸、原发性胆汁性肝硬化、随机对照试验。提取肝功能指标、临床症状、不良反应发生率、病死率等临床数据进行Meta分析。异质性研究采用随机效应模型分析,同质性研究采用固定效应模型分析。

结果

共纳入8篇文献,总计863例患者。Meta分析显示UCDA能明显改善患者ALT、AST、ALP、GGT、TB水平(SMD=-0.73,-0.87,-1.22,-1.58,-0.32;P<0.05)。UCDA不能明显改善患者瘙痒和疲劳症状,未明显增加患者不良反应发生率(OR=1.03,P>0.05),且不能明显降低患者肝移植率、病死率及肝病相关病死率(OR=0.50,0.79,0.75;P>0.05)。

结论

UCDA能明显改善PBC患者肝功能,但不能阻止PBC向终末期肝病发展、延长患者生存期或改善临床症状。

Objective

To investigate the clinical efficacy and safety of ursodesoxycholic acid (UCDA) for the treatment of primary biliary cirrhosis (PBC).

Methods

Randomized control trials literatures related to the treatment of PBC with UDCA up to October 2016 were searched by computer from PubMed, Wanfang database and CNKI. The keywords were respectively ursodeoxycholic acid, ursodiol, primary biliary cirrhosis and random clinical trials both in Chinese and English. Clinical data including liver function indexes, clinical symptoms, incidence of adverse reactions and mortality were extracted and subjected to Meta-analysis. Heterogenous studies were analyzed using random effect model, and homogenous studies were analyzed using fixed effect model.

Results

A total of 863 patients in 8 literatures were included in this study. Meta-analysis indicated that UCDA could significantly improve the levels of ALT, AST, ALP, GGT and TB (SMD=-0.73, -0.87, -1.22, -1.58, -0.32; P<0.05). UCDA could not significantly improve the symptoms of pruritus and fatigue, and did not significantly increase the incidence of adverse reactions (OR=1.03, P>0.05) and decrease the liver transplantation rate, mortality and liver disease related-mortality (OR=0.50, 0.79, 0.75; P>0.05).

Conclusions

UCDA can significantly improve the liver function of the PBC patients. But it fails to prevent the progression of PBC to end-stage liver disease, prolong the survival of the patients or improve the clinical symptoms.

表1 纳入文献的基线资料及质量评分
图1 治疗组和对照组ALT比较的Meta分析森林图
图2 采用熊去氧胆酸治疗的PBC患者不良反应发生率的发表偏倚分析漏斗图
[1]
Carey EJ, Ali AH, Lindor KD. Primary biliary cirrhosis[J]. Lancet, 2015, 386(10003):1565-1575.
[2]
Hegade VS, Khanna A, Walker LJ, et al. Long-term fenofibrate treatment in primary biliary cholangitis improves biochemistry but not the UK-PBC risk score[J]. Dig Dis Sci, 2016, 61(10):3037-3044.
[3]
Zhu GQ, Shi KQ, Huang S, et al. Network meta-analysis of randomized controlled trials: efficacy and safety of UDCA-based therapies in primary biliary cirrhosis [J]. Medicine, 2015, 94(11):e609.
[4]
Simko V, Michael S, Prego V. Ursodeoxycholic therapy in chronic liver disease: a meta-analysis in primary biliary cirrhosis and in chronic hepatitis[J]. Am J Gastroenterol, 1994, 89(3):392-398.
[5]
Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis[J]. Lancet, 1999, 354(9184):1053-1060.
[6]
施健,刘苏,陈伟忠,等.中等剂量熊去氧胆酸治疗原发性胆汁性肝硬化的系统评价[J].中华消化杂志,2005,25(6):355-358.
[7]
Heathcote EJ, Cauch-Dudek K, Walker V, et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis[J]. Hepatology, 1994, 19(5): 1149-1156.
[8]
Poupon RE, Poupon R, Balkau B. Ursodiol for the long-term treatment of primary biliary cirrhosis. the UDCA-PBC Study Group[J]. N Engl J Med, 1994, 330(19): 1342-1347.
[9]
Vuoristo M, Färkkilä M, Karvonen AL, et al. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid[J]. Gastroenterology, 1995, 108(5):1470-1478.
[10]
Parés A, Caballería L, Rodés J, et al. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver[J]. J Hepatol, 2000, 32(4): 561-566.
[11]
戴善梅,邢益平,董莉,等.优思弗治疗原发性胆汁性肝硬化的疗效观察[J].实用临床医学,2006,7(10):59-60.
[12]
冀霞,胡日旺.熊去氧胆酸治疗原发性胆汁性肝硬化临床观察[J]. 中国现代医药杂志,2010,12(9):81.
[13]
袁淑芳,刘桂桃,杜新荷.熊去氧胆酸在原发性胆汁性肝硬化的疗效分析[J].新疆医学,2012,42(1):1-3.
[14]
刘平.中等剂量熊去氧胆酸治疗原发性胆汁性肝硬化的疗效研究[J].中国医药指南,2013,11(13):184-185.
[15]
Tabibian JH, Lindor KD. Primary biliary cirrhosis: safety and benefits of established and emerging therapies[J]. Expert Opin Drug Saf, 2015, 14(9): 1435-1444.
[16]
Ali AH, Carey EJ, Lindor KD. Diagnosis and management of primary biliary cirrhosis [J]. Expert Rev Clin Immunol, 2014, 10(12): 1667-1678.
[17]
Corpechot C, Carrat F, Bonnand AM, et al. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis[J]. Hepatology, 2000, 32(6): 1196-1199.
[18]
Ali AH, Tabibian JH, Carey EJ, et al. Emerging drugs for the treatment of primary biliary cholangitis[J]. Expert Opin Emerg Drugs, 2016, 21(1):39-56.
[19]
Trivedi PJ, Kumagi T, Al-Harthy N, et al. Good maternal and fetal outcomes for pregnant women with primary biliary cirrhosis[J]. Clin Gastroenterol Hepatol, 2014, 12(7):1179-1185, e1.
[20]
Cheung AC, Lapointe-Shaw L, Kowgier M, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes[J]. Aliment Pharmacol Ther, 2016, 43(2): 283-293.
[1] 张思平, 刘伟, 马鹏程. 全膝关节置换术后下肢轻度内翻对线对疗效的影响[J]. 中华关节外科杂志(电子版), 2023, 17(06): 808-817.
[2] 罗旺林, 杨传军, 许国星, 俞建国, 孙伟东, 颜文娟, 冯志. 开放性楔形胫骨高位截骨术不同植入材料的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(06): 818-826.
[3] 马鹏程, 刘伟, 张思平. 股骨髋臼撞击综合征关节镜手术中闭合关节囊的疗效影响[J]. 中华关节外科杂志(电子版), 2023, 17(05): 653-662.
[4] 陈宏兴, 张立军, 张勇, 李虎, 周驰, 凡一诺. 膝骨关节炎关节镜清理术后中药外用疗效的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(05): 663-672.
[5] 邢阳, 何爱珊, 康焱, 杨子波, 孟繁钢, 邬培慧. 前交叉韧带单束联合前外侧结构重建的Meta分析[J]. 中华关节外科杂志(电子版), 2023, 17(04): 508-519.
[6] 李雄雄, 周灿, 徐婷, 任予, 尚进. 初诊导管原位癌伴微浸润腋窝淋巴结转移率的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 466-474.
[7] 张再博, 王冰雨, 焦志凯, 檀碧波. 胃癌术后下肢深静脉血栓危险因素的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(06): 475-480.
[8] 武慧铭, 郭仁凯, 李辉宇. 机器人辅助下经自然腔道取标本手术治疗结直肠癌安全性和有效性的Meta分析[J]. 中华普通外科学文献(电子版), 2023, 17(05): 395-400.
[9] 莫闲, 杨闯. 肝硬化患者并发门静脉血栓危险因素的Meta分析[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 678-683.
[10] 丁相元, 任效瑛, 闫慧明. Desarda与Lichtenstein术对腹股沟疝疗效的Meta分析[J]. 中华疝和腹壁外科杂志(电子版), 2023, 17(03): 255-263.
[11] 刘佳铭, 孙晓容, 文健, 何晓丽, 任茂玲. 有氧运动对成人哮喘肺功能、生活质量以及哮喘控制影响的Meta分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 592-595.
[12] 段文忠, 白延霞, 徐文亭, 祁虹霞, 吕志坚. 七氟烷和丙泊酚在肝切除术中麻醉效果比较Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 640-645.
[13] 杨海龙, 邓满军, 樊羿辰, 徐梦钰, 陈芳德, 吴威浩, 张生元. 腹腔镜胆总管探查术一期缝合术后胆漏危险因素Meta分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 545-550.
[14] 徐红莉, 杨钰琳, 薛清, 张茜, 马丽虹, 邱振刚. 体外冲击波治疗非特异性腰痛疗效的系统评价和Meta分析[J]. 中华老年骨科与康复电子杂志, 2023, 09(05): 307-314.
[15] 苏慧媛, 宋洪涛, 高巍, 武忠. 针刺治疗单纯性肥胖的系统评价和Meta分析[J]. 中华针灸电子杂志, 2023, 12(03): 123-128.
阅读次数
全文


摘要